OYST News and Press, Oyster Point Pharma Inc. From 05/05/22

TYRVAYA ® Nasal Spray Net Product Revenue of $2.7 Million in Q1’22 Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care Professionals Expansion of Commercial Coverage fo...

PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that i...

PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced th...

PRINCETON, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced th...

OKYO Pharma is a UK based developer of next generation ocular therapeutics based on GPCR and MRGPR. The company plans direct Phase 2 trial of its lead candidate following a pre-IND meeting with FDA. The company has filed F-1 for an IPO of its ADSs. For further details see: ...

PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced tha...

PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced tha...

Oyster Point Pharma, Inc. (OYST) Q4 2021 Earnings Conference Call February 24, 2022 16:30 ET Company Participants Daniel Lochner - Chief Financial Officer Jeffrey Nau - President and Chief Executive Officer John Snisarenko - Chief Commercial Officer Conference Call Participants Ken Cacciatore...

The following slide deck was published by Oyster Point Pharma, Inc. in conjunction with this event. For further details see: Oyster Point Pharma (OYST) Investor Presentation - Slideshow

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q4 2021 Earnings Call Feb 24, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q4 2021 Earnings Call Transcript...